NCT00446940

Brief Summary

Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Dec 2006

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2006

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2007

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

March 11, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 13, 2007

Completed
Last Updated

September 9, 2008

Status Verified

September 1, 2008

First QC Date

March 11, 2007

Last Update Submit

September 8, 2008

Conditions

Hepatitis C

Interventions

rosuvastatinDRUG
atorvastatinDRUG

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hepatitis C

You may not qualify if:

  • HIV positivity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Hospital

Oklahoma City, Oklahoma, 73104, United States

Location

MeSH Terms

Conditions

Hepatitis C

Interventions

Rosuvastatin CalciumAtorvastatin

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsHepatitis, Viral, HumanVirus DiseasesFlaviviridae InfectionsRNA Virus InfectionsHepatitisLiver DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

SulfonamidesAmidesOrganic ChemicalsFluorobenzenesHydrocarbons, FluorinatedHydrocarbons, HalogenatedHydrocarbonsSulfonesSulfur CompoundsPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPyrrolesAzolesHeptanoic AcidsFatty AcidsLipids

Study Officials

  • Ted Bader, MD

    VA Medical Center, Oklahoma City, OK

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDIV

Study Record Dates

First Submitted

March 11, 2007

First Posted

March 13, 2007

Study Start

December 1, 2006

Study Completion

March 1, 2007

Last Updated

September 9, 2008

Record last verified: 2008-09

Locations

US(1)